Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum.

Journal Article (Journal Article)

Because persons who identify across the transgender spectrum (PATS) are a key population in human immunodeficiency virus (HIV) yet are underreported in HIV and cardiovascular research, we aimed to characterize this population within the REPRIEVE global clinical trial (n = 7770). Acceptance of gathering gender identity was high (96%). Participation by PATS was 1.7% overall, 2.4% among natal males, 0.3% among natal females, and varied across geographic regions (from 0% in sub-Saharan Africa to 2.3% in High Income Region). Thirty percent of natal male PATS identified other than transgender. Some characteristics differed by gender. Most notably, 38% of natal male PATS receiving gender-affirming treatment had waist circumference >102 cm (compared with ≤25% in other groups). Given that PATS is a key population, HIV research should routinely report trial participation and outcomes by gender in addition to natal sex, to provide the results needed to optimize medical care to PATS.

Full Text

Duke Authors

Cited Authors

  • Smeaton, LM; Kileel, EM; Grinsztejn, B; Gardner, EM; Starr, K; Murry, ML; Desvigne-Nickens, P; Alston-Smith, B; Waclawiw, MA; Cooper-Arnold, K; Madruga, JV; Sangle, S; Fitch, KV; Zanni, MV; Douglas, PS; Ribaudo, HJ; Grinspoon, SK; Klingman, KL

Published Date

  • July 9, 2020

Published In

Volume / Issue

  • 222 / Suppl 1

Start / End Page

  • S31 - S40

PubMed ID

  • 32645160

Pubmed Central ID

  • PMC7347077

Electronic International Standard Serial Number (EISSN)

  • 1537-6613

Digital Object Identifier (DOI)

  • 10.1093/infdis/jiaa213


  • eng

Conference Location

  • United States